Medical devices developer AngioDynamics has signed an agreement to acquire medical diagnostic and device firm RadiaDyne, which focuses on radiation dose monitoring technology.

Financial details of the transaction have not been disclosed.

The deal is expected to expand AngioDynamics’ Oncology unit by adding RadiaDyne’s dose monitoring platform called OARtrac, along with IsoLoc/ImmobiLoc and Alatus balloon stabilising technologies.

–– ADVERTISEMENT ––

“The dose feedback offered by the monitoring system will allow customised adaptive radiotherapy, minimise side effects and improve clinical outcomes for all types of radiation and photon beam therapy.”
OARtrac is designed to provide precise, real-time measurement of radiation doses through the company’s intracavitary device.

The dose feedback offered by the monitoring system will allow customised adaptive radiotherapy, minimise side effects and improve clinical outcomes for all types of radiation and photon beam therapy.

IsoLoc/ImmobiLoc is an endorectal technology that eliminates transient rectal gas via a gas-release tip, as well as decreases prostate motion and radiation toxicity.

The Alatus Vaginal Balloon Packing System has been developed to enable optimal dosimetry protection and minimise complications.

AngioDynamics president and CEO Jim Clemmer said: “The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio.

“We believe that together, these disruptive, patient-focused technologies will deliver safer, clinically-relevant, economically-favourable solutions for patients.”

AngioDynamics acquired BioSentry Tract Sealant System from Surgical Specialties last month.

The sealant system is intended to prevent pneumothorax in CT-guided percutaneous lung biopsy procedures. It delivers a self-expanding hydrogel plug into the pleural space which generates an airtight seal that closes pleural punctures and prevents leakage.

Clemmer said that the strategic deal for BioSentry is in line with the company’s strategy to provide safe, clinically relevant and economically favourable solutions to improve patient outcomes.